Drugs / Solfantinib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05697237 | Jan 2023 → Jun 2024 | cholangiocarcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Solfantinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05697237 ↗ |
| Modality | Small molecule | “Solfantinib is targeted at VEGFR1, 2, 3, FGFR1And CSF1R highly selective small molecule targeted therapy drugs.” NCT05697237 ↗ |